QuantaMatrix
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
QuantaMatrix makes in-vitro diagnostic (IVD) devices, instruments that test blood, urine, and other bodily fluids outside the body to detect disease, guide treatment, and predict patient outcomes.
Its products are supplied to large hospitals and independent clinical-testing laboratories in Korea and internationally. Listed on KOSDAQ, Korea's tech-focused small-cap exchange, the company focuses primarily on microbiology diagnostics, particularly devices that test for sepsis and bloodstream infections and determine which antibiotics will work against the bacteria found.
Summary is AI-generated and may contain errors · figures from DART filings
QuantaMatrix in five facts
What does QuantaMatrix do?
QuantaMatrix makes in-vitro diagnostic (IVD) devices, instruments that test blood, urine, and other bodily fluids outside the body to detect disease, guide treatment, and predict patient outcomes.
Where is QuantaMatrix listed and in which sector?
QuantaMatrix (Korean name: 퀀타매트릭스) trades under KRX code 317690 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Medical Devices.
How large is QuantaMatrix?
Its market capitalisation was US$34.1M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were QuantaMatrix's latest annual revenue and operating profit?
For fiscal year 2025, QuantaMatrix reported revenue of US$2.8M, an operating loss of US$11.7M and a net loss of US$14.7M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 47.7% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- DisclosureSep 15
- Results of extraordinary shareholders' meetingSep 15
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Sep 8
- Notice of general shareholders' meetingAug 31
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Jun 8
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
QuantaMatrix reported consolidated results for FY2025: revenue of US$2.46M (+47.7% year on year), an operating loss of US$10.4M and a net loss of US$13M.
Earnings · Mar 16 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Mar 9
- Rights offering (paid-in capital increase) decision (subsidiary)Capital raise · Feb 20
- Decision to acquire shares/equity in another company
QuantaMatrix disclosed an acquisition of SAS UNIQ QUANTAMATRIX EUROPE, worth US$2.95M.
M&A · Feb 20